

Bridgewest Perth Pharma Receives Investment Attraction Fund from Western Australian Government for Health and Medical Life Sciences

Perth, Western Australia – 18th July 2023

Bridgewest Perth Pharma Pty Ltd, parent company of CDMO NovaCina, is pleased to announce that it has been selected as a recipient of the Investment Attraction Fund by the Western Australian government. This significant achievement highlights the company's longstanding commitment to innovation and its potential to drive future growth and advancements in the healthcare industry.

The Investment Attraction Fund (IAF) is administered by the Western Australian Government to encourage new investments in the state aimed at generating local employment opportunities and fostering a more diversified economy. It aligns with the Diversify WA initiative which capitalises on WA's existing industry strengths to prioritise strategic development in sectors like defence, space, health and medical life sciences, international education, tourism, events and creative industries, mining, and energy.

As a recipient of this fund, Bridgewest Perth Pharma will receive financial support that will be instrumental in expanding its operations within Western Australia, ensuring the integral preservation of local pharmaceutical manufacturing and job opportunities.

"Through the Investment Attraction Fund, we're driving a strong and diversified economy that delivers secure, quality jobs for the future." - Premier Roger Cook.

Brett Alderson, COO of Bridgewest Perth Pharma, expressed his gratitude, congratulating the Western Australian Government for its proactive efforts in fostering growth within a critical industry:

"We are pleased to be recognised by the Western Australian government through the Investment Attraction Fund," said Brett Alderson, COO of Bridgewest Perth Pharma. "This funding will enable us to expand our manufacturing opportunities within Perth and provide future jobs and careers to our local community. We are excited about the opportunities it presents for us to strengthen our position as an industry leader and drive economic growth in Western Australia."

Bridgewest Perth Pharma expresses its sincere gratitude to the Western Australian government for the recognition and support of its endeavours. The company remains committed to fulfilling its vision of transforming the region's pharmaceutical industry into a global leader. The acquisition of this funding represents an essential milestone in the journey towards accomplishing this objective.

For media inquiries, please contact:

Brett Alderson, COO Bridgewest Perth Pharma Pty Ltd
enquiries@novacina.co
08 9362 0666